Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Dec. 6 '25)

 


    Am J Respir Crit Care Med

  1. SARMA A, Christenson SA, Shoshana BZ, Oliveira AP, et al
    Acute Respiratory Distress Syndrome Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes.
    Am J Respir Crit Care Med. 2025;211:2352-2362.
    PubMed         Abstract available


    Ann Intern Med

  2. SOUMARE A, Kapfer T, Botrel T, Adda L, et al
    Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis.
    Ann Intern Med. 2025 Dec 2. doi: 10.7326/ANNALS-25-03055.
    PubMed         Abstract available


    BMJ

  3. LOGAN M
    FDA claims 10 child deaths caused by covid-19 vaccine, vows to tighten vaccine approvals.
    BMJ. 2025;391:r2546.
    PubMed        


    Graefes Arch Clin Exp Ophthalmol

  4. NEO YN, Martinez-Alvarez L, Davagnanam I, Girafa G, et al
    Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort.
    Graefes Arch Clin Exp Ophthalmol. 2025 Nov 29. doi: 10.1007/s00417-025-06805.
    PubMed         Abstract available


    Int J Infect Dis

  5. DING Z, Yuan HY
    Viral traits from deep mutational scanning and socio-demographic context predict SARS-CoV-2 lineage fitness across diverse countries.
    Int J Infect Dis. 2025 Nov 28:108260. doi: 10.1016/j.ijid.2025.108260.
    PubMed         Abstract available

  6. CARSTENS G, Han W, Timmermanns L, van den Hof S, et al
    Longitudinal trends in the endemic symptomatic burden of COVID-19: Insights from community-based participatory virological surveillance in the Netherlands, November 2020 - April 2025.
    Int J Infect Dis. 2025 Nov 28:108264. doi: 10.1016/j.ijid.2025.108264.
    PubMed         Abstract available

  7. MITSUSHIMA S, Horiguchi H, Taniguchi K
    Survival analysis of drug effectiveness of remdesivir and dexamethasone for confirmed COVID-19 patients using Japanese medical claim data.
    Int J Infect Dis. 2025 Nov 28:108268. doi: 10.1016/j.ijid.2025.108268.
    PubMed         Abstract available


    J Infect

  8. KELLY E, Greenland M, de Whalley P, Macaulay GC, et al
    Reactogenicity and Immunogenicity following Heterologous and Homologous Third Dose COVID-19 vaccination in UK Adolescents (Com-COV3): A Randomised Controlled Non-Inferiority Trial.
    J Infect. 2025 Dec 1:106663. doi: 10.1016/j.jinf.2025.106663.
    PubMed         Abstract available


    J Med Virol

  9. HOUMADI H, Boschi C, Lefebvre M, Le Targa L, et al
    Five-Year (2017-2022) Evolutionary Dynamics of Human Coronavirus OC43 in Southern France Based on Whole Genome Next-Generation Sequencing.
    J Med Virol. 2025;97:e70726.
    PubMed         Abstract available


    J Virol

  10. KUSAKARI D, Kishimoto N, Oshiro K, Udeda Y, et al
    Targeting envelope lipids with 2,6?di?O?methyl?3?acetyl?beta?cyclodextrin impairs infectivity of SARS?CoV?2 and Japanese encephalitis virus.
    J Virol. 2025 Dec 4:e0135725. doi: 10.1128/jvi.01357.
    PubMed         Abstract available

  11. GOMAA M, Edwards KM, Wang R, El Taweel A, et al
    Local and introduced lineages drive MERS-CoV recombination in Egyptian camels.
    J Virol. 2025 Dec 4:e0064125. doi: 10.1128/jvi.00641.
    PubMed         Abstract available

  12. HUANG M, Liukang C, Liang R, Li Y, et al
    Avian coronavirus IBV-induced activation of the NLRP3-Caspase-1-IL-1beta axis in renal collecting ducts contributes to nephropathogenesis.
    J Virol. 2025 Dec 3:e0146625. doi: 10.1128/jvi.01466.
    PubMed         Abstract available


    N Engl J Med

  13. FAKHOURI F, Bomback AS, Ariceta G, Delmas Y, et al
    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.
    N Engl J Med. 2025;393:2210-2220.
    PubMed         Abstract available

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...